Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAV1-FS344

Next Previous
X
Search
Drug Profile

AAV1-FS344

Alternative Names: AAV1 vectored follistatin gene therapy - Milo Biotechnology; AAV1-Follistatin; Gene therapy-delivered myostatin inhibitor (AAV1-FS344) – Milo Biotechnology; rAAV1 CMV huFollistatin 344; rAAV1-Follistatin; rAAV1.CMV.huFollistin344

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Milo Biotechnology; Nationwide Children's Hospital
  • Class Anti-inflammatories; Gene therapies
  • Mechanism of Action Follistatin stimulants; Gene transference; Myostatin inhibitors; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Inclusion body myositis
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy; Inclusion body myositis

Most Recent Events

  • 28 Sep 2022 Discontinued - Phase-I/II for Duchenne muscular dystrophy (In adolescents, In children, In the elderly, In adults) in USA (IM)
  • 28 Sep 2022 Discontinued - Phase-I/II for Duchenne muscular dystrophy (In adults) in USA (IM)
  • 28 Sep 2022 Discontinued - Phase-I/II for Inclusion body myositis (In adults) in USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top